-
Exclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement
Friday, February 17, 2017 - 11:21am | 909Read More...On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: JNJ) to access hundreds of hypoxia inducible factor (HIF)-targeted compounds. This access includes a coveted preclinical candidate for inflammatory bowel disease (...
-
MGM, Melco Report Tuesday Amid Macau Slowdown -IBD
Monday, August 6, 2012 - 9:21am | 16Read More...View here.
-
Alcoa Flat After-Hours on Q2 Earnings -IBD
Monday, July 9, 2012 - 5:56pm | 17Read More...View article here.
